

# Aktuelle Aspekte zur Osteoprotektion bei Prostatakarzinompatienten

Thomas Steuber

## Literatur

1. Smith MR et al. Risk of clinical fractures after gonadotropin-releasing hormone against therapy for prostate cancer. *J Urol* 2006; 175: 136–9
2. Shahinian VB et al. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005 Jan 13; 352: 154–64
3. Smith MR et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009; 361: 745–55
4. Hupe MC et al. Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance. *Aktuelle Urol* 2022; 53: 43–53
5. Dachverband Osteologie (DVO) Leitlinie Osteoporose 2017, Kitteltaschenversion
6. University of Sheffield. FRAX® Fracture Risk Assessment Tool. (<https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9>) Zugegriffen: 16.09.2020
7. Coleman R et al. Bone health in cancer: ESMO Clinical Practice Guidelines. *Ann Oncol* 2020; 31: 1650–63
8. Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer *N Engl J Med* 2018; 378: 1408–18
9. Hussain M et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer *N Engl J Med* 2018; 378: 2465–74
10. Smith M et al. Addition of radium-223 to abirateroneacetate and prednisone or prednisolone in patients with castrationresistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 408–19
11. <https://clinicaltrials.gov/ct2/show/NCT02194842>
12. [https://www.leitlinienprogrammonkologie.de/fileadmin/user\\_upload/Downloads/Leitlinien/Prostatakarzinom/Version\\_6/LL\\_Prostatakarzinom\\_Langversion\\_6.2.pdf](https://www.leitlinienprogrammonkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatakarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.2.pdf)
13. Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002; 94: 1458–68
14. Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. *Lancet* 2011; 377: 813–22
15. Smith MR et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). *J Clin Oncol* 2014; 32: 1143–50
16. Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371: 424–33